While we have focused on FRC-CD8+ T cell interactions, we envision that DLBCL-FRCs also modulate other key immune subsets that reside within the TME, which is supported by our data showing upregulated chemoattractants such as Ccl2 for macrophages. The gene discussed is CCL2; the disease is diffuse large B-cell lymphoma.